Labroots and the Drug Discovery planning committee are pleased to announce its 2nd annual event in the Drug Discovery Virtual Event Series. The event will remain open 6 months from the date of the live event. The webinars will be available for unlimited on-demand viewing.
Drug Discovery 2019 brought together industry leaders from around the world will join together and discuss the advancements, challenges and successes of discovery and development of new medications and therapies. Don't miss the opportunity to participate in this groundbreaking conference, which is absolutely free to all participants.
Continuing Education
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this event, you can earn 1 Continuing Education credit per presentation for a maximum of 30 credits.
Use #LRdrug to follow the conversation!
Professor of the UCSF Helen Diller Family Comprehensive Cancer Center
DISCOVERY Reagent & Training Lead, Companion Diagnostics (CDx) & DISCOVERY, Roche Tissue Diagnostics
Vice President of Business Development, Advanced Cell Diagnostics
President & CEO, Aptagen, LLC
Chief Commercial Officer, Somark Innovations
Clinical Oncology Marketing, Illumina, Inc.
Vice President and General Manager, Corning Life Sciences
Chief Medical Officer, Illumina, Inc.
Associate Director, Charles River Laboratories
Founder and Chief Scientist, Base Pair Biotechnologies
CEO, MIP Diagnostics
Senior Vice President, Research & Development, ModMab Therapeutics, Inc.
Professor of Medicine (Oncology) and of Radiology (Molecular Imaging Program at Stanford), Director Phase I Clinical Research, Director, Translational Oncology Program, Stanford University
University Veterinarian & Director, Laboratory Animal Resources Center, University of Texas at San Antonio
Senior Field Application Scientist, QIAGEN Advanced Genomics
Scientist of Application Development, Mimetas - The Organ on a Chip Company
Global Product Manager Cell Separation, Miltenyi Biotec
Post Doctoral Research Scholar at University of California, San Francisco
Business Development, AroCell AB
Chief Operating Officer, HµREL Corporation
Senior Director of Advanced Applications, NanoString Technologies
Founder and CEO, Insilico Medicine, Inc.
Roche Diagnostics develops and produces medical tests and digital tools that provide information to help healthcare professionals find the right treatment for patients and deliver the best patient care to improve, prolong and save lives. Currently, Roche Diagnostics leads the ...
See moreAs a startup, Illumina aspired to transform human health. Our initial products enabled researchers to explore DNA at an entirely new scale, helping them create the first map of gene variations associated with health, disease, and drug response. Every breakthrough opened up a new ...
See moreNanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications ...
See moreFor over 30 years, Miltenyi Biotec has been a leader in the development of products that empower the advancement of biomedical research and enable cell and gene therapy. We provide innovative tools to help with your sample preparation, cell isolation, cell culture, and cell ...
See moreHorizon Discovery Group PLC is a world leader in the utilization of gene editing and gene modulation technologies to support the greater understanding of gene function, the genetic drivers behind human disease and the development of molecular, cell and gene therapies to enable ...
See moreLI-COR first introduced scientific instruments for plant science research and quickly grew to provide scientists tools for such diverse disciplines as atmospheric research and the study of how proteins interact at the cellular level. LI-COR Biosciences is a global leader in the ...
See moreACD shortens the path to personalized medicine by unlocking the power of RNA biomarkers. Advanced Cell Diagnostics, Inc. (ACD) is a leader in the emerging field of molecular pathology, developing cell- and tissue-based diagnostic tests for personalized medicine. Based in the ...
See moreAn Associate Professor with Midwestern University, Dr. Annette Gilchrist has a PhD in Immunology from the University of Connecticut Health Center and a MS in Biochemistry from the University of Connecticut. Previously, she was with Cue Biotech and Caden Biosciences, companies she ...
See moreMatt entered the research field over 20 years ago as a lab animal technician at the TSI/Mason contract research facility. He has worked at both contract facilities such as TSI and OREAD Biosafety as well in industry at Pharmacia, Pfizer, and Sanofi-Aventis. During that period he ...
See moreKhyati Shah received her Ph.D. in Molecular Pharmacology from the University of the Pacific, Stockton, California. Her graduate research was completed in the lab of Jesika Faridi, Ph.D. Her work focused on the investigation of the mechanism of Akt induced tamoxifen resistance in ...
See moreBetween 1994-2015 he worked at EKF Diagnostics in Wales (formerly Argutus Medical) where he introduced and promoted a wide range of novel kidney and liver tests, including important biomarkers that are now being evaluated by the IMI (Innovative Medicines Initiative) and FDA as ...
See moreOver the past 16 years, Mr. Shipton has amassed deep domain expertise in cell-based products and services. Currently serving as President of Novabiosis, Inc. Mr. Shipton brings a skill for implementing sales-driven business strategies, an extensive track record of meeting and ...
See moreSid Topiol is the founder and CSO of 3D-2drug LLC, a collaborative research organization incubating drug discovery projects. 3D-2drug is rooted in the deployment of protein structure/function information into novel and efficient drug discovery opportunities. Sid received his B.S ...
See more